INmune Bio
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $50 | $0 | $0 |
Gross Profit | 50 | |||
EBITDA | -24,571 | -9,905 | -9,218 | -12,286 |
EBIT | -18,934 | |||
Net Income | -24,458 | -9,739 | -9,218 | -12,093 |
Net Change In Cash | 0 | 50 | 0 | 0 |
Free Cash Flow | -8,080 | -6,824 | -11,013 | -6,986 |
Cash | 33,374 | 19,337 | 20,922 | 33,552 |
Basic Shares | 23,298 | 22,496 | 22,280 | 20,186 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $14 | $155 | $374 | $181 |
Gross Profit | 14 | 155 | 374 | 181 |
EBITDA | -42,082 | -29,741 | -27,299 | -30,340 |
EBIT | -42,635 | -59,482 | -25,951 | -29,153 |
Net Income | -42,082 | -30,008 | -28,647 | -30,340 |
Net Change In Cash | 14 | 155 | 374 | 181 |
Cost of Revenue | -21,957 | 52,843 | ||
Free Cash Flow | -33,361 | -11,980 | -22,686 | -43,504 |
Cash | 20,922 | 35,848 | 52,153 | 74,810 |
Basic Shares | 19,944 | 17,981 | 17,927 | 16,131 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.34 |
2025-03-31 | -$0.43 |
2024-12-31 | -$0.40 |
